DYN · Insider trading · 13F holders · Congress trades
Dyne Therapeutics, Inc. (DYN)
Who is buying and selling DYN: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 28
- Insider buys, 90 days
- $40K
- Insider sales, 90 days
- $65.7M
- Congress trades, 12 months
- 0
DYN at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 6 DYN insiders filed 1 open-market purchase worth $40K and 8 sales worth $65.7M on SEC Form 4; 8 of the sales were pre-planned under Rule 10b5-1.
- 28 13F filers hold DYN among their 50 largest positions, worth $1.2B combined, including Joseph Edelman and Robert Pohly. The biggest bets by portfolio weight are Fcpm III Services B.v. (11.4%), Palo Alto Investors LP (5.1%) and Saturn V Capital Management LP (3.4%). In their latest 13Fs, 1 manager opened a new position and 6 added to one.
- No member of Congress has disclosed a trade in DYN.
- DYN last closed at $17.04 on Oct 29, 2026.
DYN insider trading
Between Aug 1, 2026 and Oct 29, 2026, 6 DYN insiders filed 1 open-market purchase worth $40K and 8 sales worth $65.7M on SEC Form 4; 8 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Posner Brian S | Director | Buy | 2,500 | $16.00 | $40K | SEC |
| Sep 8, 2026 | Kerr Douglas | Chief Medical Officer | Sale10b5-1 | 5,035 | $22.95 | $116K | SEC |
| Sep 8, 2026 | Cox John | CEO & President, Director | Sale10b5-1 | 5,658 | $18.88 | $107K | SEC |
| Sep 8, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sale10b5-1 | 1,085 | $23.42 | $25K | SEC |
| Aug 17, 2026 | Rhodes Jason P | Director | Sale10b5-1 | 2,586,928 | $25.20 | $65.2M | SEC |
| Aug 17, 2026 | Cox John | CEO & President, Director | Sale10b5-1 | 4,986 | $26.28 | $131K | SEC |
| Aug 17, 2026 | Lucera Erick | Chief Financial Officer | Sale10b5-1 | 1,797 | $26.28 | $47K | SEC |
| Aug 17, 2026 | Kerr Douglas | Chief Medical Officer | Sale10b5-1 | 1,556 | $26.28 | $41K | SEC |
| Aug 17, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sale10b5-1 | 226 | $26.28 | $6K | SEC |
Who owns DYN? Hedge funds and superinvestors
28 13F filers hold DYN among their 50 largest positions, worth $1.2B combined, including Joseph Edelman and Robert Pohly. The biggest bets by portfolio weight are Fcpm III Services B.v. (11.4%), Palo Alto Investors LP (5.1%) and Saturn V Capital Management LP (3.4%). In their latest 13Fs, 1 manager opened a new position and 6 added to one.
Superinvestors holding DYN: Joseph Edelman 0.9% · Robert Pohly 0.6%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLCVenture capital | 17.1% | $151.0M | 6,800,099 | -25.5% shares | Q2 2026 |
| TCG Crossover Management, LLCHedge fund | 2.5% | $102.5M | 4,615,144 | +0.0% shares | Q2 2026 |
| Fcpm III Services B.v.Hedge fund | 11.4% | $85.5M | 3,848,256 | -17.1% shares | Q2 2026 |
| Vestal Point Capital, LPHedge fund | 1.8% | $75.0M | 3,375,000 | -15.6% shares | Q2 2026 |
| Orbimed Advisors LLCHedge fund | 1.4% | $71.9M | 3,235,684 | +10.9% shares | Q2 2026 |
| Frazier Life Sciences Management, L.P.Hedge fund | 1.5% | $70.0M | 3,153,082 | +0.0% shares | Q2 2026 |
| Armistice Capital, LLCHedge fund | 1.9% | $68.6M | 3,087,226 | -2.8% shares | Q2 2026 |
| Joseph EdelmanHedge fund | 0.9% | $59.7M | 2,689,235 | -42.4% shares | Q2 2026 |
| Logos Global Management LPHedge fund | 2.4% | $56.6M | 2,550,000 | +82.1% shares | Q2 2026 |
| Venrock Adviser, LLCHedge fund | 1.5% | $48.3M | 2,173,913 | +0.0% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 1.0% | $47.3M | 2,129,125 | -4.5% shares | Q2 2026 |
| Mpm Bioimpact LLCHedge fund | 2.6% | $42.7M | 1,922,093 | +36.5% shares | Q2 2026 |
| Robert PohlyHedge fund | 0.6% | $39.0M | 1,754,708 | — | Q2 2026 |
| Sofinnova Investments, Inc.Hedge fund | 2.0% | $36.8M | 1,658,384 | +1.5% shares | Q2 2026 |
| Palo Alto Investors LPHedge fund | 5.1% | $36.6M | 1,647,521 | -0.3% shares | Q2 2026 |
| Vivo Capital, LLCHedge fund | 3.2% | $34.6M | 1,557,466 | +0.0% shares | Q2 2026 |
| Deep Track Capital, LPHedge fund | 0.5% | $33.3M | 1,500,000 | -25.0% shares | Q2 2026 |
| Saturn V Capital Management LPHedge fund | 3.4% | $23.5M | 1,057,493 | +9.4% shares | Q2 2026 |
| Novo Holdings A/sInvestment manager | 1.2% | $21.3M | 960,394 | New | Q2 2026 |
| Rock Springs Capital Management LPHedge fund | 1.0% | $20.9M | 942,154 | -3.1% shares | Q2 2026 |
| Tetragon Partners GP LtdHedge fund | 1.3% | $7.9M | 356,657 | +38.2% shares | Q2 2026 |
| University of Wisconsin FoundationEndowment & foundation | 5.5% | $7.0M | 313,559 | -35.3% shares | Q2 2026 |
| Catalio Capital Management, LPHedge fund | 1.0% | $5.4M | 244,929 | -13.4% shares | Q2 2026 |
| HighVista Strategies LLCHedge fund | 0.9% | $3.8M | 171,961 | -6.0% shares | Q2 2026 |
| Darwin Wealth Management, LLCWealth manager | 0.9% | $3.4M | 155,270 | +0.3% shares | Q2 2026 |
| Aegis Wealth Management LLCWealth manager | 1.6% | $3.3M | 150,030 | +11.1% shares | Q2 2026 |
| Lion Point Capital, LPHedge fund | 1.9% | $400K | 18,000 | +0.0% shares | Q2 2026 |
| PSP Research LLCInstitutional asset manager | 0.1% | $161K | 10,000 | -50.0% shares | Q3 2026 |
Each manager counts with its latest 13F (Q3 2026: 1, Q2 2026: 27). Screen DYN in the grand portfolio →
DYN stock trades by members of Congress
No member of Congress has disclosed a trade in DYN.
Analysis mentioning DYN
Posts from the blog that cover Dyne Therapeutics, Inc., newest first.
DYN questions and answers
Are insiders buying DYN stock?
Between Aug 1, 2026 and Oct 29, 2026, 6 DYN insiders filed 1 open-market purchase worth $40K and 8 sales worth $65.7M on SEC Form 4; 8 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own DYN?
28 13F filers hold DYN among their 50 largest positions, worth $1.2B combined, including Joseph Edelman and Robert Pohly. The biggest bets by portfolio weight are Fcpm III Services B.v. (11.4%), Palo Alto Investors LP (5.1%) and Saturn V Capital Management LP (3.4%). In their latest 13Fs, 1 manager opened a new position and 6 added to one.
Has Congress traded DYN?
No member of Congress has disclosed a trade in DYN.
Who is the largest holder of DYN?
Among 13F filers, Atlas Venture Life Science Advisors, LLC reports the largest DYN position, $151.0M (6,800,099 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Fcpm III Services B.v.'s: 11.4% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.